Purdue Research Foundation

Endocyte, Inc.

Seattle Children's Hospital

Yingjuan June Lu

Philip Stewart Low

Christopher Paul Leamon

Haiyan Chu

Leroy W Wheeler, Ii

Michael C Jensen

James Matthaei

Iontcho Radoslavov Vlahov

Hari Krishna R Santhapuram

Paul Joseph Kleindl

Kevin Yu Wang

Yong Gu Lee

Fei You

Julie Ruggieri Park

Fei Yu

Richard Messmann

Navin Robert Charles Pinto

Leroy W Wheeler Ii

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Methods of use for CAR T cells

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Sequencing method for CAR T cell therapy

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Compositions and methods for CAR T cell therapy

Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.

Vitamin receptor drug delivery conjugates for treating inflammation

A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.

Method of treatment using ligand-immunogen conjugates

Growing community of inventors

West Lafayette, IN, United States of America

Yingjuan June Lu